Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LatviaBack to Latvia

Clinical trials in Jelgava

7 clinical trials in Jelgava, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Jelgava at a glance
7
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

7 trials in Jelgava

Open in trial search

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Major depression

Recruiting

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Major depression

Recruiting

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Jelgava

What the registry says about research in the country

01 Diabetes Management Studies

Clinical investigations focusing on type 2 diabetes management through combination therapy approaches. Research evaluates the effectiveness of gliclazide MR when combined with existing treatments.

  • Treatment Optimization
  • Glycemic Control
  • Combination Therapy

Studies aim to improve blood sugar control in patients not achieving optimal results with current medications.

02 Diabetic Eye Disease Research

Groundbreaking research examining the impact of semaglutide on diabetic retinopathy in patients with type 2 diabetes. This long-term safety study evaluates treatment effects on eye health.

  • Retinopathy Development
  • Disease Progression
  • Ophthalmologic Assessment

The research includes standardized ophthalmic evaluations to monitor disease progression and treatment outcomes.

03 Therapeutic Safety Studies

Post-authorization safety assessments conducted under European Medicines Agency oversight, focusing on long-term effects of diabetes treatments.

  • Safety Monitoring
  • Long-term Outcomes
  • Treatment Effects

These studies contribute to understanding the complete safety profile of new diabetes medications.

Back to LatviaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.